cbdMD Leadership to Attend Mid-Atlantic Legislative Conference on June 1 in WV

Charlotte, North Carolina–(Newsfile Corp. – June 1, 2022) – cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), one of the nation’s leading and most highly trusted and recognized CBD companies and operator of three of the leading CBD brands – its flagship brand cbdMD, its animal health brand Paw CBD and its beauty and skincare brand cbdMD Botanicals – will be in attendance at the 2022 Mid-Atlantic Legislative Conference in White Sulphur Springs, West Virginia as presented by the West Virginia Wholesalers Association (WVWA). cbdMD will be represented by Kit Dietz (Keynote Presentation), Lance Blundell (Leading Panelist) and Dr. Sibyl Swift (Leading Panelist).

The conference is set to run on June 1 and June 2, featuring panel discussions on the current state of affairs for hemp-derived products. The main focus of these panel discussions will be new product innovations and changes to the 2023 Farm Bill. Innovations include Delta 9 THC and its recent rise in popularity, while panelists will also explore how any changes to the Farm Bill will affect how hemp products are sold in stores.

Kit Dietz currently serves as a Strategic Advisor to the CEO & Board of Directors with an exclusive focus on improving convenience store supply chain while continuing to push into all major food, drug and mass merchandise (“FDM”) retailers in the U.S. Before launching Dietz Consulting, LLC in early 2003, Dietz served as an independent outside Director of Lorillard, Inc. for seven years. He brings a deep understanding of supply chain and margin costs while enhancing performance profitability by leveraging collaborative opportunities.

Lance Blundell and Dr. Sibyl Swift will represent cbdMD in the panel discussions. As the General Counsel for cbdMD, Blundell brings expertise in hemp-derived product regulation and legality. Dr. Swift, former Senior VP for Scientific & Regulatory Affairs at the Natural Products Association (NPA) and Associate Director for Research & Strategy at the U.S. Food and Drug Administration (FDA), currently acts as the Vice President for Scientific & Regulatory Affairs at cbdMD, Inc. Dr. Swift oversees the Company’s GMP compliance internal product quality and safety initiatives and directs scientific work performed in support of worldwide regulatory submissions and claims substantiation.

About cbdMD, Inc.

cbdMD, Inc. is one of the leading and most highly trusted and most recognized hemp-derived cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free¹ CBD products as well as our Full Spectrum and Delta 9 THC products. Our cbdMD brand currently includes high-quality, premium CBD products including tinctures, gummies, topicals, capsules, bath bombs, sleep aids and drink mixes. Our Paw CBD brand of pet products includes veterinarian-formulated products including tinctures, chews and topicals in varying strengths, and our cbdMD Botanicals brand of beauty and skincare products features facial oil and serum, toners, moisturizers, facial masks, exfoliants and body care. To learn more about cbdMD and their comprehensive line of products, please visit www.cbdmd.com, follow cbdMD on Instagram and Facebook, or visit one of the thousands of retail outlets that carry cbdMD products.

Forward-Looking Statements

This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified using words such as ”should,” ”may,” ”intends,” ”anticipates,” ”believes,” ”estimates,” ”projects,” ”forecasts,” ”expects,” ”plans,” and ”proposes.” These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. You are urged to carefully review and consider any cautionary statements, including but not limited to expectations on cost reductions, and other disclosures, including the statements made under the heading “Risk Factors” in cbdMD, Inc.’s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 as filed with the Securities and Exchange Commission (the “SEC”) on December 17, 2021 and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.

¹THC-free is defined as below the level of detection using validated scientific analytical tools.

Contacts:
cbdMD, Inc.
John Weston
Director of Investor Relations
john.weston@cbdmd.com
(704) 249-9515

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/126177